New pill targets Hard-to-Treat cancers with MAPK mutations
Disease control
Ongoing
This early-phase study tests a new oral drug, D3S-002, in adults with advanced solid tumors that have MAPK pathway mutations and have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can control tumor growth. A…
Phase: PHASE1, PHASE2 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC